Previous 10 | Next 10 |
Trinity Biotech press release ( NASDAQ: TRIB ): Q1 GAAP EPADS of -50c. Revenue of $18.78M (-26.6% Y/Y) misses by $1.22M . For further details see: Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2022. ...
DUBLIN, Ireland, June 29, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursday, June 30...
Trinity Biotech (NASDAQ:TRIB) said on Friday it had achieved the European CE Mark or approval for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The test in clinical trails had demonstrated 99% sensitivity and 99% spe...
DUBLIN, Ireland, May 20, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The Company intends to launch the test throughout the European Unio...
DUBLIN, Ireland, May 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its recently announced strategic investment with the Mi...
Trinity Biotech press release (NASDAQ:TRIB): Q4 GAAP EPADS of -0.4 cents. Revenue of $19.53M (-40.4% Y/Y). Gross profit for Q4, 2021 amounted to $7.2M equating to a gross margin of 37.1%, compared to the 47.8% reported in the equivalent quarter last year. For further details see: Trinit...
Trinity Biotech (NASDAQ:TRIB) stated Monday that it has secured $45M equity plus debt investment in partnership deal with listed Korean biomedical company - MiCo. The investment comprises of 11.2M Trinity ADS at price of $2.25, following which MiCo will hold 29.9% ownership in the ...
DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal year 2021. ...
DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading global diagnostic company (“Trinity Biotech” or the “Company”), today announced a $45 million strategic investment and partnership with MiCo Ltd (“MiCo”...
News, Short Squeeze, Breakout and More Instantly...
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (...
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to at...
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”...